Vitamin B3 study explores how body handles supplement during illness
NCT ID NCT07156929
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at how a special form of vitamin B3 (nicotinamide) is processed in 28 patients with low tryptophan levels due to respiratory infections or inflammatory bowel disease. Participants took either 500 mg or 1000 mg of the supplement daily for four weeks. The main goal was to measure changes in vitamin B3 and related substances in the blood, not to test if it treats the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- controlled-ileocolonic-release nicotinamide (a special form of vitamin B3)
- What this could lead to
- If successful, this could help design better vitamin B3 supplements for people with low tryptophan levels due to infections or chronic inflammation.
- What could go wrong
- This is a small, early study with only 28 participants and no control group. It mainly measures how the body processes the supplement, not whether it improves health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
28 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Serum tryptophan levels below normal range. * Acute, infectious respiratory disease requiring treatment (e.g. proven acute SARS-CoV-2 or influenza virus infection with inpatient treatment) or chronic inflammatory disease (e.g. chronic inflammatory bowel disease) in remission or in acute relapse (outpatient or inpatient treatment). Exclusion Criteria: * Inability to give informed consent. * Pregnancy or breastfeeding. * Serious other illness, e.g. cancer. * Anemia: Hb \<10 mg/dL. * Intake of medication to raise the pH value in the stomach (e.g. proton pump inhibitors, H2 receptor antagonists or antacids) in higher doses over a longer period of time.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Community acquired pneumonia (CAP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, 24105, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI learns to measure bowel inflammation from ultrasound
- Ancient remedies put to the test against pneumonia in the elderly
- Can pressurized oxygen heal Crohn's fistulas when drugs fail?
- Do vegan yogurts and meat substitutes really boost your gut?
- Could a simple workout routine tame IBD symptoms?
- Could a new pill tame inflammatory bowel disease? early safety trial begins